JP4933527B2 - リポカリンタンパク質 - Google Patents

Info

Publication number

JP4933527B2

JP4933527B2 JP2008500259A JP2008500259A JP4933527B2 JP 4933527 B2 JP4933527 B2 JP 4933527B2 JP 2008500259 A JP2008500259 A JP 2008500259A JP 2008500259 A JP2008500259 A JP 2008500259A JP 4933527 B2 JP4933527 B2 JP 4933527B2

Authority

JP

Japan

Prior art keywords

polypeptide

insp181

seq

sequence

cell

Prior art date

2005-03-08

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Expired - Fee Related

Links

• Espacenet
• Global Dossier
• Discuss

• 102000019298 Lipocalin Human genes 0.000 title claims description 82
• 108050006654 Lipocalin Proteins 0.000 title claims description 82
• 108090000765 processed proteins & peptides Proteins 0.000 claims description 599
• 102000004196 processed proteins & peptides Human genes 0.000 claims description 581
• 229920001184 polypeptide Polymers 0.000 claims description 575
• 150000007523 nucleic acids Chemical class 0.000 claims description 130
• 102000039446 nucleic acids Human genes 0.000 claims description 126
• 108020004707 nucleic acids Proteins 0.000 claims description 126
• 239000012634 fragment Substances 0.000 claims description 61
• 102220510486 Ras-related C3 botulinum toxin substrate 2_N92T_mutation Human genes 0.000 claims description 50
• 239000013598 vector Substances 0.000 claims description 50
• 150000001413 amino acids Chemical class 0.000 claims description 44
• 238000011282 treatment Methods 0.000 claims description 33
• 238000004519 manufacturing process Methods 0.000 claims description 25
• 125000003275 alpha amino acid group Chemical group 0.000 claims description 24
• 102000003814 Interleukin-10 Human genes 0.000 claims description 23
• 108090000174 Interleukin-10 Proteins 0.000 claims description 23
• 102000004388 Interleukin-4 Human genes 0.000 claims description 23
• 108090000978 Interleukin-4 Proteins 0.000 claims description 23
• 201000004681 Psoriasis Diseases 0.000 claims description 22
• 238000006467 substitution reaction Methods 0.000 claims description 22
• 230000028327 secretion Effects 0.000 claims description 20
• 239000003814 drug Substances 0.000 claims description 19
• 108010002616 Interleukin-5 Proteins 0.000 claims description 17
• 239000008194 pharmaceutical composition Substances 0.000 claims description 11
• 108090000623 proteins and genes Proteins 0.000 description 190
• 210000004027 cell Anatomy 0.000 description 179
• 238000000034 method Methods 0.000 description 160
• 150000001875 compounds Chemical class 0.000 description 109
• 230000014509 gene expression Effects 0.000 description 101
• 102000004169 proteins and genes Human genes 0.000 description 101
• 235000018102 proteins Nutrition 0.000 description 98
• 238000003556 assay Methods 0.000 description 92
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 91
• 201000010099 disease Diseases 0.000 description 85
• 238000003752 polymerase chain reaction Methods 0.000 description 83
• 108020004414 DNA Proteins 0.000 description 80
• 230000000694 effects Effects 0.000 description 69
• 241000282414 Homo sapiens Species 0.000 description 65
• 239000000203 mixture Substances 0.000 description 64
• 235000001014 amino acid Nutrition 0.000 description 53
• 238000006243 chemical reaction Methods 0.000 description 50
• 230000027455 binding Effects 0.000 description 49
• 238000009739 binding Methods 0.000 description 49
• 239000002299 complementary DNA Substances 0.000 description 49
• 239000003446 ligand Substances 0.000 description 48
• 239000000523 sample Substances 0.000 description 47
• 229940024606 amino acid Drugs 0.000 description 45
• 239000013612 plasmid Substances 0.000 description 44
• 102000004127 Cytokines Human genes 0.000 description 42
• 108090000695 Cytokines Proteins 0.000 description 42
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 42
• 239000000047 product Substances 0.000 description 41
• 239000005557 antagonist Substances 0.000 description 33
• 238000012216 screening Methods 0.000 description 33
• 238000012360 testing method Methods 0.000 description 33
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 30
• 230000006870 function Effects 0.000 description 28
• 108020001507 fusion proteins Proteins 0.000 description 28
• 102000037865 fusion proteins Human genes 0.000 description 28
• 210000001519 tissue Anatomy 0.000 description 27
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 26
• 125000003729 nucleotide group Chemical group 0.000 description 26
• 239000000556 agonist Substances 0.000 description 25
• 230000035772 mutation Effects 0.000 description 25
• 239000002773 nucleotide Substances 0.000 description 25
• 230000001225 therapeutic effect Effects 0.000 description 24
• 230000005856 abnormality Effects 0.000 description 22
• 108020004999 messenger RNA Proteins 0.000 description 22
• 208000017520 skin disease Diseases 0.000 description 22
• 238000010367 cloning Methods 0.000 description 21
• 229940076144 interleukin-10 Drugs 0.000 description 21
• 238000000746 purification Methods 0.000 description 21
• 229940028885 interleukin-4 Drugs 0.000 description 20
• 230000001105 regulatory effect Effects 0.000 description 19
• 238000012163 sequencing technique Methods 0.000 description 19
• 102000004190 Enzymes Human genes 0.000 description 18
• 108090000790 Enzymes Proteins 0.000 description 18
• 239000000872 buffer Substances 0.000 description 18
• 238000003745 diagnosis Methods 0.000 description 18
• 229940088598 enzyme Drugs 0.000 description 18
• 230000015572 biosynthetic process Effects 0.000 description 17
• 230000004048 modification Effects 0.000 description 17
• 238000012986 modification Methods 0.000 description 17
• 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 17
• 108010062580 Concanavalin A Proteins 0.000 description 16
• 108091034117 Oligonucleotide Proteins 0.000 description 16
• 230000003321 amplification Effects 0.000 description 16
• 239000003795 chemical substances by application Substances 0.000 description 16
• 238000000338 in vitro Methods 0.000 description 16
• 238000003199 nucleic acid amplification method Methods 0.000 description 16
• 102000005962 receptors Human genes 0.000 description 16
• 108020003175 receptors Proteins 0.000 description 16
• 239000000126 substance Substances 0.000 description 16
• 102100039897 Interleukin-5 Human genes 0.000 description 15
• 238000004458 analytical method Methods 0.000 description 15
• 239000011324 bead Substances 0.000 description 15
• 238000009396 hybridization Methods 0.000 description 15
• 229940100602 interleukin-5 Drugs 0.000 description 15
• 239000003550 marker Substances 0.000 description 15
• 238000013459 approach Methods 0.000 description 14
• 238000001727 in vivo Methods 0.000 description 14
• 230000004044 response Effects 0.000 description 14
• 239000000243 solution Substances 0.000 description 14
• 230000001580 bacterial effect Effects 0.000 description 13
• 239000012472 biological sample Substances 0.000 description 13
• 230000000295 complement effect Effects 0.000 description 13
• 238000001514 detection method Methods 0.000 description 13
• 239000013604 expression vector Substances 0.000 description 13
• 235000014304 histidine Nutrition 0.000 description 13
• 210000003491 skin Anatomy 0.000 description 13
• 108091026890 Coding region Proteins 0.000 description 12
• 238000001712 DNA sequencing Methods 0.000 description 12
• 241001465754 Metazoa Species 0.000 description 12
• 206010028980 Neoplasm Diseases 0.000 description 12
• 210000001744 T-lymphocyte Anatomy 0.000 description 12
• 125000000539 amino acid group Chemical group 0.000 description 12
• 210000000170 cell membrane Anatomy 0.000 description 12
• 239000003153 chemical reaction reagent Substances 0.000 description 12
• 229940079593 drug Drugs 0.000 description 12
• -1 fumaric acid ester Chemical class 0.000 description 12
• 239000000499 gel Substances 0.000 description 12
• 239000012528 membrane Substances 0.000 description 12
• 239000006228 supernatant Substances 0.000 description 12
• 241000196324 Embryophyta Species 0.000 description 11
• 206010020751 Hypersensitivity Diseases 0.000 description 11
• 108010076504 Protein Sorting Signals Proteins 0.000 description 11
• 238000007792 addition Methods 0.000 description 11
• 239000011543 agarose gel Substances 0.000 description 11
• FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 11
• 230000007815 allergy Effects 0.000 description 11
• 230000000890 antigenic effect Effects 0.000 description 11
• 201000011510 cancer Diseases 0.000 description 11
• 238000005755 formation reaction Methods 0.000 description 11
• 238000002360 preparation method Methods 0.000 description 11
• 239000011541 reaction mixture Substances 0.000 description 11
• 239000007787 solid Substances 0.000 description 11
• 238000013519 translation Methods 0.000 description 11
• 230000014616 translation Effects 0.000 description 11
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 10
• 206010009900 Colitis ulcerative Diseases 0.000 description 10
• 208000022559 Inflammatory bowel disease Diseases 0.000 description 10
• 241000124008 Mammalia Species 0.000 description 10
• 201000006704 Ulcerative Colitis Diseases 0.000 description 10
• JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 10
• 230000000692 anti-sense effect Effects 0.000 description 10
• 238000004113 cell culture Methods 0.000 description 10
• 230000002068 genetic effect Effects 0.000 description 10
• 230000012010 growth Effects 0.000 description 10
• 230000002209 hydrophobic effect Effects 0.000 description 10
• 230000008569 process Effects 0.000 description 10
• 238000007390 skin biopsy Methods 0.000 description 10
• 208000024891 symptom Diseases 0.000 description 10
• 229960005486 vaccine Drugs 0.000 description 10
• 208000011231 Crohn disease Diseases 0.000 description 9
• 206010012438 Dermatitis atopic Diseases 0.000 description 9
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
• 102100037850 Interferon gamma Human genes 0.000 description 9
• 108010074328 Interferon-gamma Proteins 0.000 description 9
• 108010051335 Lipocalin-2 Proteins 0.000 description 9
• 102000013519 Lipocalin-2 Human genes 0.000 description 9
• 101150102573 PCR1 gene Proteins 0.000 description 9
• 108010006785 Taq Polymerase Proteins 0.000 description 9
• 108060008682 Tumor Necrosis Factor Proteins 0.000 description 9
• 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 9
• 241000700605 Viruses Species 0.000 description 9
• 201000008937 atopic dermatitis Diseases 0.000 description 9
• 230000004071 biological effect Effects 0.000 description 9
• 210000001124 body fluid Anatomy 0.000 description 9
• 239000010839 body fluid Substances 0.000 description 9
• 238000005516 engineering process Methods 0.000 description 9
• 230000001965 increasing effect Effects 0.000 description 9
• 238000003786 synthesis reaction Methods 0.000 description 9
• MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 8
• 101100519158 Arabidopsis thaliana PCR2 gene Proteins 0.000 description 8
• 108091028043 Nucleic acid sequence Proteins 0.000 description 8
• 229960000723 ampicillin Drugs 0.000 description 8
• AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 8
• 238000000423 cell based assay Methods 0.000 description 8
• 239000013592 cell lysate Substances 0.000 description 8
• 230000000875 corresponding effect Effects 0.000 description 8
• 239000003937 drug carrier Substances 0.000 description 8
• 238000002474 experimental method Methods 0.000 description 8
• 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 8
• 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 8
• 208000015181 infectious disease Diseases 0.000 description 8
• 210000004962 mammalian cell Anatomy 0.000 description 8
• BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 8
• 102000040430 polynucleotide Human genes 0.000 description 8
• 108091033319 polynucleotide Proteins 0.000 description 8
• 239000002157 polynucleotide Substances 0.000 description 8
• 150000003384 small molecules Chemical class 0.000 description 8
• 239000008223 sterile water Substances 0.000 description 8
• 230000000638 stimulation Effects 0.000 description 8
• 208000023275 Autoimmune disease Diseases 0.000 description 7
• 108090000994 Catalytic RNA Proteins 0.000 description 7
• 102000053642 Catalytic RNA Human genes 0.000 description 7
• 108020004705 Codon Proteins 0.000 description 7
• 201000004624 Dermatitis Diseases 0.000 description 7
• 241000588724 Escherichia coli Species 0.000 description 7
• 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 7
• 108010002350 Interleukin-2 Proteins 0.000 description 7
• 102000000588 Interleukin-2 Human genes 0.000 description 7
• 208000026935 allergic disease Diseases 0.000 description 7
• 230000000845 anti-microbial effect Effects 0.000 description 7
• 208000010668 atopic eczema Diseases 0.000 description 7
• 238000001574 biopsy Methods 0.000 description 7
• 238000012217 deletion Methods 0.000 description 7
• 230000037430 deletion Effects 0.000 description 7
• 238000001415 gene therapy Methods 0.000 description 7
• 230000002757 inflammatory effect Effects 0.000 description 7
• 238000003780 insertion Methods 0.000 description 7
• 230000037431 insertion Effects 0.000 description 7
• 201000010260 leiomyoma Diseases 0.000 description 7
• 238000012423 maintenance Methods 0.000 description 7
• 201000006417 multiple sclerosis Diseases 0.000 description 7
• 238000002703 mutagenesis Methods 0.000 description 7
• 231100000350 mutagenesis Toxicity 0.000 description 7
• 201000005962 mycosis fungoides Diseases 0.000 description 7
• 230000002062 proliferating effect Effects 0.000 description 7
• 230000001850 reproductive effect Effects 0.000 description 7
• 238000011160 research Methods 0.000 description 7
• 238000003757 reverse transcription PCR Methods 0.000 description 7
• 108091092562 ribozyme Proteins 0.000 description 7
• 239000000758 substrate Substances 0.000 description 7
• 230000009466 transformation Effects 0.000 description 7
• 230000032258 transport Effects 0.000 description 7
• 230000003612 virological effect Effects 0.000 description 7
• FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 6
• 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 6
• 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 6
• 238000002965 ELISA Methods 0.000 description 6
• 238000012408 PCR amplification Methods 0.000 description 6
• 108091093037 Peptide nucleic acid Proteins 0.000 description 6
• 239000004698 Polyethylene Substances 0.000 description 6
• 239000008049 TAE buffer Substances 0.000 description 6
• HGEVZDLYZYVYHD-UHFFFAOYSA-N acetic acid;2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid Chemical compound CC(O)=O.OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O HGEVZDLYZYVYHD-UHFFFAOYSA-N 0.000 description 6
• 230000004913 activation Effects 0.000 description 6
• 150000003862 amino acid derivatives Chemical class 0.000 description 6
• 208000006673 asthma Diseases 0.000 description 6
• 230000008827 biological function Effects 0.000 description 6
• 239000002158 endotoxin Substances 0.000 description 6
• 210000001508 eye Anatomy 0.000 description 6
• 230000013595 glycosylation Effects 0.000 description 6
• 238000006206 glycosylation reaction Methods 0.000 description 6
• 239000003112 inhibitor Substances 0.000 description 6
• 230000005764 inhibitory process Effects 0.000 description 6
• 238000002347 injection Methods 0.000 description 6
• 239000007924 injection Substances 0.000 description 6
• 230000003834 intracellular effect Effects 0.000 description 6
• 239000002609 medium Substances 0.000 description 6
• 210000000440 neutrophil Anatomy 0.000 description 6
• 238000003127 radioimmunoassay Methods 0.000 description 6
• 230000006798 recombination Effects 0.000 description 6
• 238000005215 recombination Methods 0.000 description 6
• 210000002966 serum Anatomy 0.000 description 6
• 230000035939 shock Effects 0.000 description 6
• 239000000725 suspension Substances 0.000 description 6
• 230000008685 targeting Effects 0.000 description 6
• 238000013518 transcription Methods 0.000 description 6
• 230000035897 transcription Effects 0.000 description 6
• 206010006187 Breast cancer Diseases 0.000 description 5
• 208000026310 Breast neoplasm Diseases 0.000 description 5
• 206010012442 Dermatitis contact Diseases 0.000 description 5
• 206010014561 Emphysema Diseases 0.000 description 5
• 241000282412 Homo Species 0.000 description 5
• 241000699666 Mus <mouse, genus> Species 0.000 description 5
• 108020004711 Nucleic Acid Probes Proteins 0.000 description 5
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 5
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
• 230000002159 abnormal effect Effects 0.000 description 5
• 238000010171 animal model Methods 0.000 description 5
• 239000000427 antigen Substances 0.000 description 5
• 108091007433 antigens Proteins 0.000 description 5
• 102000036639 antigens Human genes 0.000 description 5
• 206010003246 arthritis Diseases 0.000 description 5
• 210000004369 blood Anatomy 0.000 description 5
• 239000008280 blood Substances 0.000 description 5
• 239000000969 carrier Substances 0.000 description 5
• 238000001516 cell proliferation assay Methods 0.000 description 5
• 238000004587 chromatography analysis Methods 0.000 description 5
• 230000002759 chromosomal effect Effects 0.000 description 5
• 210000000349 chromosome Anatomy 0.000 description 5
• 238000003776 cleavage reaction Methods 0.000 description 5
• 208000010247 contact dermatitis Diseases 0.000 description 5
• 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 5
• 230000004069 differentiation Effects 0.000 description 5
• 239000000284 extract Substances 0.000 description 5
• 238000001943 fluorescence-activated cell sorting Methods 0.000 description 5
• 210000004565 granule cell Anatomy 0.000 description 5
• 230000002163 immunogen Effects 0.000 description 5
• 230000001939 inductive effect Effects 0.000 description 5
• 238000011081 inoculation Methods 0.000 description 5
• 230000003993 interaction Effects 0.000 description 5
• 239000000463 material Substances 0.000 description 5
• 238000002493 microarray Methods 0.000 description 5
• 208000010125 myocardial infarction Diseases 0.000 description 5
• PXHVJJICTQNCMI-UHFFFAOYSA-N nickel Substances [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 5
• 239000002853 nucleic acid probe Substances 0.000 description 5
• 210000001672 ovary Anatomy 0.000 description 5
• 238000012545 processing Methods 0.000 description 5
• 238000004393 prognosis Methods 0.000 description 5
• 230000035755 proliferation Effects 0.000 description 5
• 229960003471 retinol Drugs 0.000 description 5
• 235000020944 retinol Nutrition 0.000 description 5
• 239000011607 retinol Substances 0.000 description 5
• 230000002441 reversible effect Effects 0.000 description 5
• 230000007017 scission Effects 0.000 description 5
• 238000010561 standard procedure Methods 0.000 description 5
• 230000009261 transgenic effect Effects 0.000 description 5
• 230000000007 visual effect Effects 0.000 description 5
• 230000029663 wound healing Effects 0.000 description 5
• VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 4
• 208000035143 Bacterial infection Diseases 0.000 description 4
• 206010006220 Breast cyst Diseases 0.000 description 4
• 102000014914 Carrier Proteins Human genes 0.000 description 4
• 108020004635 Complementary DNA Proteins 0.000 description 4
• 102000053602 DNA Human genes 0.000 description 4
• 238000009007 Diagnostic Kit Methods 0.000 description 4
• 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
• 201000009273 Endometriosis Diseases 0.000 description 4
• 108010067770 Endopeptidase K Proteins 0.000 description 4
• 101710147132 Epididymal-specific lipocalin-5 Proteins 0.000 description 4
• 206010015150 Erythema Diseases 0.000 description 4
• 102000016359 Fibronectins Human genes 0.000 description 4
• 108010067306 Fibronectins Proteins 0.000 description 4
• ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
• 206010017533 Fungal infection Diseases 0.000 description 4
• 102100028967 HLA class I histocompatibility antigen, alpha chain G Human genes 0.000 description 4
• 108010024164 HLA-G Antigens Proteins 0.000 description 4
• 241000238631 Hexapoda Species 0.000 description 4
• 101001019591 Homo sapiens Interleukin-18-binding protein Proteins 0.000 description 4
• 102100035017 Interleukin-18-binding protein Human genes 0.000 description 4
• 239000006142 Luria-Bertani Agar Substances 0.000 description 4
• 208000031888 Mycoses Diseases 0.000 description 4
• 208000001140 Night Blindness Diseases 0.000 description 4
• 206010036774 Proctitis Diseases 0.000 description 4
• 108010029485 Protein Isoforms Proteins 0.000 description 4
• 102000001708 Protein Isoforms Human genes 0.000 description 4
• 102000006382 Ribonucleases Human genes 0.000 description 4
• 108010083644 Ribonucleases Proteins 0.000 description 4
• 238000012300 Sequence Analysis Methods 0.000 description 4
• 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 4
• 239000007984 Tris EDTA buffer Substances 0.000 description 4
• 208000036142 Viral infection Diseases 0.000 description 4
• 230000001154 acute effect Effects 0.000 description 4
• 238000001042 affinity chromatography Methods 0.000 description 4
• 238000013528 artificial neural network Methods 0.000 description 4
• 208000022362 bacterial infectious disease Diseases 0.000 description 4
• 210000004899 c-terminal region Anatomy 0.000 description 4
• 238000010804 cDNA synthesis Methods 0.000 description 4
• 230000030833 cell death Effects 0.000 description 4
• 230000004663 cell proliferation Effects 0.000 description 4
• 238000005119 centrifugation Methods 0.000 description 4
• 230000008859 change Effects 0.000 description 4
• 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 4
• 230000002950 deficient Effects 0.000 description 4
• 238000010790 dilution Methods 0.000 description 4
• 239000012895 dilution Substances 0.000 description 4
• 231100000673 dose–response relationship Toxicity 0.000 description 4
• 239000003623 enhancer Substances 0.000 description 4
• 231100000321 erythema Toxicity 0.000 description 4
• 229960005309 estradiol Drugs 0.000 description 4
• 229930182833 estradiol Natural products 0.000 description 4
• 231100000502 fertility decrease Toxicity 0.000 description 4
• PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 4
• 229910052737 gold Inorganic materials 0.000 description 4
• 239000010931 gold Substances 0.000 description 4
• 210000000987 immune system Anatomy 0.000 description 4
• 229930027917 kanamycin Natural products 0.000 description 4
• 229960000318 kanamycin Drugs 0.000 description 4
• SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 4
• 229930182823 kanamycin A Natural products 0.000 description 4
• 239000007788 liquid Substances 0.000 description 4
• 210000002540 macrophage Anatomy 0.000 description 4
• 230000001404 mediated effect Effects 0.000 description 4
• 230000000813 microbial effect Effects 0.000 description 4
• 230000002025 microglial effect Effects 0.000 description 4
• 210000001616 monocyte Anatomy 0.000 description 4
• 229910052759 nickel Inorganic materials 0.000 description 4
• 239000000816 peptidomimetic Substances 0.000 description 4
• 229910052697 platinum Inorganic materials 0.000 description 4
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
• 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 4
• 210000002307 prostate Anatomy 0.000 description 4
• 238000000159 protein binding assay Methods 0.000 description 4
• 230000002829 reductive effect Effects 0.000 description 4
• 230000008085 renal dysfunction Effects 0.000 description 4
• 150000004492 retinoid derivatives Chemical class 0.000 description 4
• 102000029752 retinol binding Human genes 0.000 description 4
• 108091000053 retinol binding Proteins 0.000 description 4
• 238000012552 review Methods 0.000 description 4
• 210000003079 salivary gland Anatomy 0.000 description 4
• 238000007423 screening assay Methods 0.000 description 4
• 230000003248 secreting effect Effects 0.000 description 4
• 238000002741 site-directed mutagenesis Methods 0.000 description 4
• 241000894007 species Species 0.000 description 4
• 238000001890 transfection Methods 0.000 description 4
• 241000701447 unidentified baculovirus Species 0.000 description 4
• 230000003827 upregulation Effects 0.000 description 4
• FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 description 3
• 102000005606 Activins Human genes 0.000 description 3
• 108010059616 Activins Proteins 0.000 description 3
• 206010004146 Basal cell carcinoma Diseases 0.000 description 3
• 208000023328 Basedow disease Diseases 0.000 description 3
• 108010078791 Carrier Proteins Proteins 0.000 description 3
• 102000000844 Cell Surface Receptors Human genes 0.000 description 3
• 208000002691 Choroiditis Diseases 0.000 description 3
• 206010048768 Dermatosis Diseases 0.000 description 3
• 108010013369 Enteropeptidase Proteins 0.000 description 3
• 102100029727 Enteropeptidase Human genes 0.000 description 3
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
• 101150112014 Gapdh gene Proteins 0.000 description 3
• 235000010469 Glycine max Nutrition 0.000 description 3
• NMJREATYWWNIKX-UHFFFAOYSA-N GnRH Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CC(C)C)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 NMJREATYWWNIKX-UHFFFAOYSA-N 0.000 description 3
• 208000015023 Graves' disease Diseases 0.000 description 3
• 208000001204 Hashimoto Disease Diseases 0.000 description 3
• 208000030836 Hashimoto thyroiditis Diseases 0.000 description 3
• 208000005176 Hepatitis C Diseases 0.000 description 3
• 108060003951 Immunoglobulin Proteins 0.000 description 3
• 102100034343 Integrase Human genes 0.000 description 3
• 102000003815 Interleukin-11 Human genes 0.000 description 3
• 108090000177 Interleukin-11 Proteins 0.000 description 3
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
• 102000003752 Lipocalin 1 Human genes 0.000 description 3
• 108010057281 Lipocalin 1 Proteins 0.000 description 3
• 108060001084 Luciferase Proteins 0.000 description 3
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
• 241000283973 Oryctolagus cuniculus Species 0.000 description 3
• 102000004264 Osteopontin Human genes 0.000 description 3
• 108010081689 Osteopontin Proteins 0.000 description 3
• 208000003971 Posterior uveitis Diseases 0.000 description 3
• 206010039085 Rhinitis allergic Diseases 0.000 description 3
• 208000009359 Sezary Syndrome Diseases 0.000 description 3
• 208000021388 Sezary disease Diseases 0.000 description 3
• 108010003723 Single-Domain Antibodies Proteins 0.000 description 3
• 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 3
• 108091008874 T cell receptors Proteins 0.000 description 3
• 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 3
• 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 3
• 206010046798 Uterine leiomyoma Diseases 0.000 description 3
• 208000009621 actinic keratosis Diseases 0.000 description 3
• 239000000488 activin Substances 0.000 description 3
• 210000004100 adrenal gland Anatomy 0.000 description 3
• 201000010105 allergic rhinitis Diseases 0.000 description 3
• 229930193936 anticarin Natural products 0.000 description 3
• 210000003719 b-lymphocyte Anatomy 0.000 description 3
• 108091008324 binding proteins Proteins 0.000 description 3
• 230000033228 biological regulation Effects 0.000 description 3
• 230000000903 blocking effect Effects 0.000 description 3
• 210000004556 brain Anatomy 0.000 description 3
• 238000012512 characterization method Methods 0.000 description 3
• 210000001072 colon Anatomy 0.000 description 3
• 239000013068 control sample Substances 0.000 description 3
• 230000002596 correlated effect Effects 0.000 description 3
• 230000001351 cycling effect Effects 0.000 description 3
• SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 3
• SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 3
• RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 3
• HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 3
• 238000013461 design Methods 0.000 description 3
• 238000011161 development Methods 0.000 description 3
• 230000018109 developmental process Effects 0.000 description 3
• 229960000633 dextran sulfate Drugs 0.000 description 3
• 238000007876 drug discovery Methods 0.000 description 3
• 238000007877 drug screening Methods 0.000 description 3
• 210000003527 eukaryotic cell Anatomy 0.000 description 3
• 230000035558 fertility Effects 0.000 description 3
• 239000012530 fluid Substances 0.000 description 3
• 238000009472 formulation Methods 0.000 description 3
• 230000004927 fusion Effects 0.000 description 3
• 239000003862 glucocorticoid Substances 0.000 description 3
• 210000002443 helper t lymphocyte Anatomy 0.000 description 3
• 210000000688 human artificial chromosome Anatomy 0.000 description 3
• 230000028993 immune response Effects 0.000 description 3
• 238000003018 immunoassay Methods 0.000 description 3
• 102000018358 immunoglobulin Human genes 0.000 description 3
• 238000007901 in situ hybridization Methods 0.000 description 3
• 230000006698 induction Effects 0.000 description 3
• 238000002955 isolation Methods 0.000 description 3
• 210000003734 kidney Anatomy 0.000 description 3
• 230000003902 lesion Effects 0.000 description 3
• 150000002632 lipids Chemical class 0.000 description 3
• 239000002502 liposome Substances 0.000 description 3
• 239000011159 matrix material Substances 0.000 description 3
• 238000005259 measurement Methods 0.000 description 3
• 201000008350 membranous glomerulonephritis Diseases 0.000 description 3
• 230000002018 overexpression Effects 0.000 description 3
• 230000001575 pathological effect Effects 0.000 description 3
• 229920001223 polyethylene glycol Polymers 0.000 description 3
• 102000054765 polymorphisms of proteins Human genes 0.000 description 3
• 230000000069 prophylactic effect Effects 0.000 description 3
• 238000003753 real-time PCR Methods 0.000 description 3
• 238000011084 recovery Methods 0.000 description 3
• 230000015069 regulation of nervous system development Effects 0.000 description 3
• 206010039073 rheumatoid arthritis Diseases 0.000 description 3
• 150000003839 salts Chemical class 0.000 description 3
• 201000000306 sarcoidosis Diseases 0.000 description 3
• 238000002864 sequence alignment Methods 0.000 description 3
• 239000011780 sodium chloride Substances 0.000 description 3
• 229940124597 therapeutic agent Drugs 0.000 description 3
• 206010043778 thyroiditis Diseases 0.000 description 3
• 210000002993 trophoblast Anatomy 0.000 description 3
• 241001515965 unidentified phage Species 0.000 description 3
• 210000002700 urine Anatomy 0.000 description 3
• 210000004325 uterine smooth muscle cell Anatomy 0.000 description 3
• 230000009385 viral infection Effects 0.000 description 3
• QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical class C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 3
• 239000011534 wash buffer Substances 0.000 description 3
• 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
• OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 2
• 241000972773 Aulopiformes Species 0.000 description 2
• 230000020955 B cell costimulation Effects 0.000 description 2
• 241000894006 Bacteria Species 0.000 description 2
• 241000282472 Canis lupus familiaris Species 0.000 description 2
• 241000701489 Cauliflower mosaic virus Species 0.000 description 2
• 108010001857 Cell Surface Receptors Proteins 0.000 description 2
• 241000282693 Cercopithecidae Species 0.000 description 2
• 206010009137 Chronic sinusitis Diseases 0.000 description 2
• 108091033380 Coding strand Proteins 0.000 description 2
• 108010035532 Collagen Proteins 0.000 description 2
• 102000008186 Collagen Human genes 0.000 description 2
• 208000037845 Cutaneous squamous cell carcinoma Diseases 0.000 description 2
• IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 2
• 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
• 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 2
• 206010061818 Disease progression Diseases 0.000 description 2
• 241000701959 Escherichia virus Lambda Species 0.000 description 2
• 108700024394 Exon Proteins 0.000 description 2
• 201000008808 Fibrosarcoma Diseases 0.000 description 2
• 229920001917 Ficoll Polymers 0.000 description 2
• 102100039556 Galectin-4 Human genes 0.000 description 2
• 206010018364 Glomerulonephritis Diseases 0.000 description 2
• 244000068988 Glycine max Species 0.000 description 2
• 101000608765 Homo sapiens Galectin-4 Proteins 0.000 description 2
• 101000946124 Homo sapiens Lipocalin-1 Proteins 0.000 description 2
• PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 2
• 206010020649 Hyperkeratosis Diseases 0.000 description 2
• 206010061218 Inflammation Diseases 0.000 description 2
• 102000003816 Interleukin-13 Human genes 0.000 description 2
• 108090000176 Interleukin-13 Proteins 0.000 description 2
• 208000001126 Keratosis Diseases 0.000 description 2
• 229930182816 L-glutamine Natural products 0.000 description 2
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
• 102100034724 Lipocalin-1 Human genes 0.000 description 2
• 239000004472 Lysine Substances 0.000 description 2
• 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 2
• 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
• 241001467552 Mycobacterium bovis BCG Species 0.000 description 2
• MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
• 108020005187 Oligonucleotide Probes Proteins 0.000 description 2
• 229910019142 PO4 Inorganic materials 0.000 description 2
• 239000002202 Polyethylene glycol Substances 0.000 description 2
• 206010037083 Prurigo Diseases 0.000 description 2
• REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
• 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 2
• 239000013614 RNA sample Substances 0.000 description 2
• 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
• 241000700159 Rattus Species 0.000 description 2
• 108020004511 Recombinant DNA Proteins 0.000 description 2
• 108700008625 Reporter Genes Proteins 0.000 description 2
• 241000283984 Rodentia Species 0.000 description 2
• 108020004682 Single-Stranded DNA Proteins 0.000 description 2
• 108700012920 TNF Proteins 0.000 description 2
• 102000002933 Thioredoxin Human genes 0.000 description 2
• 108010022394 Threonine synthase Proteins 0.000 description 2
• 241000723873 Tobacco mosaic virus Species 0.000 description 2
• 102000002689 Toll-like receptor Human genes 0.000 description 2
• 108020000411 Toll-like receptor Proteins 0.000 description 2
• 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 2
• 108050002568 Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 description 2
• IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 2
• DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
• 210000000683 abdominal cavity Anatomy 0.000 description 2
• 239000002253 acid Substances 0.000 description 2
• 230000009471 action Effects 0.000 description 2
• 210000004102 animal cell Anatomy 0.000 description 2
• 239000004599 antimicrobial Substances 0.000 description 2
• 238000006664 bond formation reaction Methods 0.000 description 2
• 230000003491 cAMP production Effects 0.000 description 2
• 239000011575 calcium Substances 0.000 description 2
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
• 230000015556 catabolic process Effects 0.000 description 2
• HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
• 208000027157 chronic rhinosinusitis Diseases 0.000 description 2
• 239000013599 cloning vector Substances 0.000 description 2
• 229920001436 collagen Polymers 0.000 description 2
• 230000009918 complex formation Effects 0.000 description 2
• 230000021615 conjugation Effects 0.000 description 2
• 108091036078 conserved sequence Proteins 0.000 description 2
• 239000003246 corticosteroid Substances 0.000 description 2
• 238000004132 cross linking Methods 0.000 description 2
• 210000004748 cultured cell Anatomy 0.000 description 2
• VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 2
• 229940095074 cyclic amp Drugs 0.000 description 2
• 235000018417 cysteine Nutrition 0.000 description 2
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
• 230000016396 cytokine production Effects 0.000 description 2
• NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 2
• 230000016117 decidualization Effects 0.000 description 2
• 230000007423 decrease Effects 0.000 description 2
• 230000003247 decreasing effect Effects 0.000 description 2
• 238000006731 degradation reaction Methods 0.000 description 2
• 238000004925 denaturation Methods 0.000 description 2
• 230000036425 denaturation Effects 0.000 description 2
• 238000002405 diagnostic procedure Methods 0.000 description 2
• 230000029087 digestion Effects 0.000 description 2
• 102000004419 dihydrofolate reductase Human genes 0.000 description 2
• 239000003085 diluting agent Substances 0.000 description 2
• 230000005750 disease progression Effects 0.000 description 2
• 239000012153 distilled water Substances 0.000 description 2
• 238000009826 distribution Methods 0.000 description 2
• 230000008482 dysregulation Effects 0.000 description 2
• 210000002472 endoplasmic reticulum Anatomy 0.000 description 2
• 210000000981 epithelium Anatomy 0.000 description 2
• 238000000605 extraction Methods 0.000 description 2
• 239000007850 fluorescent dye Substances 0.000 description 2
• 230000030279 gene silencing Effects 0.000 description 2
• 230000009368 gene silencing by RNA Effects 0.000 description 2
• 238000012226 gene silencing method Methods 0.000 description 2
• 238000007429 general method Methods 0.000 description 2
• 230000001434 glomerular Effects 0.000 description 2
• 210000003714 granulocyte Anatomy 0.000 description 2
• UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
• 102000043827 human Smooth muscle Human genes 0.000 description 2
• 108700038605 human Smooth muscle Proteins 0.000 description 2
• 210000004408 hybridoma Anatomy 0.000 description 2
• 229910052739 hydrogen Inorganic materials 0.000 description 2
• 239000001257 hydrogen Substances 0.000 description 2
• 230000001900 immune effect Effects 0.000 description 2
• 230000003832 immune regulation Effects 0.000 description 2
• 230000036039 immunity Effects 0.000 description 2
• 230000005847 immunogenicity Effects 0.000 description 2
• 239000002955 immunomodulating agent Substances 0.000 description 2
• 229940121354 immunomodulator Drugs 0.000 description 2
• 230000002584 immunomodulator Effects 0.000 description 2
• 238000002513 implantation Methods 0.000 description 2
• 239000012535 impurity Substances 0.000 description 2
• 238000011065 in-situ storage Methods 0.000 description 2
• 238000010348 incorporation Methods 0.000 description 2
• 238000011534 incubation Methods 0.000 description 2
• 230000004054 inflammatory process Effects 0.000 description 2
• 230000002401 inhibitory effect Effects 0.000 description 2
• 210000000936 intestine Anatomy 0.000 description 2
• 238000007918 intramuscular administration Methods 0.000 description 2
• 238000001990 intravenous administration Methods 0.000 description 2
• 230000009545 invasion Effects 0.000 description 2
• BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
• MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 2
• 238000007834 ligase chain reaction Methods 0.000 description 2
• 230000007774 longterm Effects 0.000 description 2
• 210000004072 lung Anatomy 0.000 description 2
• 210000004698 lymphocyte Anatomy 0.000 description 2
• 108010082117 matrigel Proteins 0.000 description 2
• 230000035800 maturation Effects 0.000 description 2
• 229910052751 metal Inorganic materials 0.000 description 2
• 239000002184 metal Substances 0.000 description 2
• 229960000485 methotrexate Drugs 0.000 description 2
• 244000005700 microbiome Species 0.000 description 2
• 210000000274 microglia Anatomy 0.000 description 2
• 239000003226 mitogen Substances 0.000 description 2
• 238000010369 molecular cloning Methods 0.000 description 2
• 230000008271 nervous system development Effects 0.000 description 2
• 238000007857 nested PCR Methods 0.000 description 2
• 230000007935 neutral effect Effects 0.000 description 2
• 230000003472 neutralizing effect Effects 0.000 description 2
• 238000007899 nucleic acid hybridization Methods 0.000 description 2
• 239000002751 oligonucleotide probe Substances 0.000 description 2
• 238000002515 oligonucleotide synthesis Methods 0.000 description 2
• 210000000287 oocyte Anatomy 0.000 description 2
• 230000002611 ovarian Effects 0.000 description 2
• 238000004806 packaging method and process Methods 0.000 description 2
• 239000002245 particle Substances 0.000 description 2
• 230000001717 pathogenic effect Effects 0.000 description 2
• 230000037361 pathway Effects 0.000 description 2
• 235000021317 phosphate Nutrition 0.000 description 2
• 150000008300 phosphoramidites Chemical class 0.000 description 2
• 230000001817 pituitary effect Effects 0.000 description 2
• 201000010065 polycystic ovary syndrome Diseases 0.000 description 2
• 230000001323 posttranslational effect Effects 0.000 description 2
• 230000035935 pregnancy Effects 0.000 description 2
• 230000002265 prevention Effects 0.000 description 2
• 210000001236 prokaryotic cell Anatomy 0.000 description 2
• BHMBVRSPMRCCGG-OUTUXVNYSA-N prostaglandin D2 Chemical compound CCCCC[C@H](O)\C=C\[C@@H]1[C@@H](C\C=C/CCCC(O)=O)[C@@H](O)CC1=O BHMBVRSPMRCCGG-OUTUXVNYSA-N 0.000 description 2
• BHMBVRSPMRCCGG-UHFFFAOYSA-N prostaglandine D2 Natural products CCCCCC(O)C=CC1C(CC=CCCCC(O)=O)C(O)CC1=O BHMBVRSPMRCCGG-UHFFFAOYSA-N 0.000 description 2
• 210000000064 prostate epithelial cell Anatomy 0.000 description 2
• 238000001742 protein purification Methods 0.000 description 2
• 230000006337 proteolytic cleavage Effects 0.000 description 2
• ZCCUUQDIBDJBTK-UHFFFAOYSA-N psoralen Chemical compound C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 description 2
• 230000001185 psoriatic effect Effects 0.000 description 2
• BBNQQADTFFCFGB-UHFFFAOYSA-N purpurin Chemical compound C1=CC=C2C(=O)C3=C(O)C(O)=CC(O)=C3C(=O)C2=C1 BBNQQADTFFCFGB-UHFFFAOYSA-N 0.000 description 2
• 239000011535 reaction buffer Substances 0.000 description 2
• 230000009467 reduction Effects 0.000 description 2
• 230000010076 replication Effects 0.000 description 2
• QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 2
• 230000001177 retroviral effect Effects 0.000 description 2
• 235000019515 salmon Nutrition 0.000 description 2
• 230000035945 sensitivity Effects 0.000 description 2
• 201000010106 skin squamous cell carcinoma Diseases 0.000 description 2
• 239000001509 sodium citrate Substances 0.000 description 2
• 239000001488 sodium phosphate Substances 0.000 description 2
• 229910000162 sodium phosphate Inorganic materials 0.000 description 2
• 239000007790 solid phase Substances 0.000 description 2
• 239000002904 solvent Substances 0.000 description 2
• 230000009870 specific binding Effects 0.000 description 2
• 210000000952 spleen Anatomy 0.000 description 2
• 206010041823 squamous cell carcinoma Diseases 0.000 description 2
• 150000003431 steroids Chemical class 0.000 description 2
• 210000002784 stomach Anatomy 0.000 description 2
• 229960005322 streptomycin Drugs 0.000 description 2
• 238000007920 subcutaneous administration Methods 0.000 description 2
• 230000008961 swelling Effects 0.000 description 2
• 229940037128 systemic glucocorticoids Drugs 0.000 description 2
• 230000002123 temporal effect Effects 0.000 description 2
• 210000001550 testis Anatomy 0.000 description 2
• 238000002560 therapeutic procedure Methods 0.000 description 2
• 108060008226 thioredoxin Proteins 0.000 description 2
• 229940094937 thioredoxin Drugs 0.000 description 2
• RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
• 238000012546 transfer Methods 0.000 description 2
• 230000005945 translocation Effects 0.000 description 2
• HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 2
• 229940038773 trisodium citrate Drugs 0.000 description 2
• RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
• 230000009452 underexpressoin Effects 0.000 description 2
• 241000701161 unidentified adenovirus Species 0.000 description 2
• 210000004291 uterus Anatomy 0.000 description 2
• 239000003981 vehicle Substances 0.000 description 2
• 238000005406 washing Methods 0.000 description 2
• 238000001262 western blot Methods 0.000 description 2
• 210000005253 yeast cell Anatomy 0.000 description 2
• PSQYTAPXSHCGMF-BQYQJAHWSA-N β-ionone Chemical compound CC(=O)\C=C\C1=C(C)CCCC1(C)C PSQYTAPXSHCGMF-BQYQJAHWSA-N 0.000 description 2
• SFEOKXHPFMOVRM-UHFFFAOYSA-N (+)-(S)-gamma-ionone Natural products CC(=O)C=CC1C(=C)CCCC1(C)C SFEOKXHPFMOVRM-UHFFFAOYSA-N 0.000 description 1
• WAMWSIDTKSNDCU-ZETCQYMHSA-N (2s)-2-azaniumyl-2-cyclohexylacetate Chemical compound OC(=O)[C@@H](N)C1CCCCC1 WAMWSIDTKSNDCU-ZETCQYMHSA-N 0.000 description 1
• UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 1
• IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
• OMGHIGVFLOPEHJ-UHFFFAOYSA-N 2,5-dihydro-1h-pyrrol-1-ium-2-carboxylate Chemical compound OC(=O)C1NCC=C1 OMGHIGVFLOPEHJ-UHFFFAOYSA-N 0.000 description 1
• 101150090724 3 gene Proteins 0.000 description 1
• VXGRJERITKFWPL-UHFFFAOYSA-N 4',5'-Dihydropsoralen Natural products C1=C2OC(=O)C=CC2=CC2=C1OCC2 VXGRJERITKFWPL-UHFFFAOYSA-N 0.000 description 1
• QSUSKMBNZQHHPA-UHFFFAOYSA-N 4-[4-(4-fluorophenyl)-1-(3-phenylpropyl)-5-pyridin-4-ylimidazol-2-yl]but-3-yn-1-ol Chemical compound C=1C=CC=CC=1CCCN1C(C#CCCO)=NC(C=2C=CC(F)=CC=2)=C1C1=CC=NC=C1 QSUSKMBNZQHHPA-UHFFFAOYSA-N 0.000 description 1
• 101150057816 4.3 gene Proteins 0.000 description 1
• ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
• 230000005730 ADP ribosylation Effects 0.000 description 1
• 101150094949 APRT gene Proteins 0.000 description 1
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
• 229930024421 Adenine Natural products 0.000 description 1
• GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
• 102100029457 Adenine phosphoribosyltransferase Human genes 0.000 description 1
• 108010024223 Adenine phosphoribosyltransferase Proteins 0.000 description 1
• 108700028369 Alleles Proteins 0.000 description 1
• 244000153158 Ammi visnaga Species 0.000 description 1
• 235000010585 Ammi visnaga Nutrition 0.000 description 1
• 108010032595 Antibody Binding Sites Proteins 0.000 description 1
• 108020004491 Antisense DNA Proteins 0.000 description 1
• 102000013933 Apolipoproteins D Human genes 0.000 description 1
• 108010025614 Apolipoproteins D Proteins 0.000 description 1
• 239000004475 Arginine Substances 0.000 description 1
• DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
• 241000228212 Aspergillus Species 0.000 description 1
• 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
• 206010003645 Atopy Diseases 0.000 description 1
• 238000012935 Averaging Methods 0.000 description 1
• 244000063299 Bacillus subtilis Species 0.000 description 1
• 235000014469 Bacillus subtilis Nutrition 0.000 description 1
• 231100000699 Bacterial toxin Toxicity 0.000 description 1
• 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
• 241000219310 Beta vulgaris subsp. vulgaris Species 0.000 description 1
• 241000283690 Bos taurus Species 0.000 description 1
• 101000800130 Bos taurus Thyroglobulin Proteins 0.000 description 1
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
• 102100024167 C-C chemokine receptor type 3 Human genes 0.000 description 1
• 101710149862 C-C chemokine receptor type 3 Proteins 0.000 description 1
• 101710149863 C-C chemokine receptor type 4 Proteins 0.000 description 1
• 102100021935 C-C motif chemokine 26 Human genes 0.000 description 1
• 102100032367 C-C motif chemokine 5 Human genes 0.000 description 1
• 102100032976 CCR4-NOT transcription complex subunit 6 Human genes 0.000 description 1
• 101100180402 Caenorhabditis elegans jun-1 gene Proteins 0.000 description 1
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
• 241000283707 Capra Species 0.000 description 1
• 108010055166 Chemokine CCL5 Proteins 0.000 description 1
• 206010008631 Cholera Diseases 0.000 description 1
• 108700010070 Codon Usage Proteins 0.000 description 1
• 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
• 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
• 229920000742 Cotton Polymers 0.000 description 1
• 241000699800 Cricetinae Species 0.000 description 1
• 241000699802 Cricetulus griseus Species 0.000 description 1
• PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
• 108010036949 Cyclosporine Proteins 0.000 description 1
• UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 1
• DZLNHFMRPBPULJ-GSVOUGTGSA-N D-thioproline Chemical compound OC(=O)[C@H]1CSCN1 DZLNHFMRPBPULJ-GSVOUGTGSA-N 0.000 description 1
• 108010017826 DNA Polymerase I Proteins 0.000 description 1
• 102000004594 DNA Polymerase I Human genes 0.000 description 1
• 102000003915 DNA Topoisomerases Human genes 0.000 description 1
• 108090000323 DNA Topoisomerases Proteins 0.000 description 1
• 239000003298 DNA probe Substances 0.000 description 1
• 230000004568 DNA-binding Effects 0.000 description 1
• 229920002307 Dextran Polymers 0.000 description 1
• 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
• 238000012286 ELISA Assay Methods 0.000 description 1
• 108010042407 Endonucleases Proteins 0.000 description 1
• 102000004533 Endonucleases Human genes 0.000 description 1
• 241000283086 Equidae Species 0.000 description 1
• 241000283073 Equus caballus Species 0.000 description 1
• 108700039887 Essential Genes Proteins 0.000 description 1
• 108010008165 Etanercept Proteins 0.000 description 1
• 108060002716 Exonuclease Proteins 0.000 description 1
• 108050001049 Extracellular proteins Proteins 0.000 description 1
• 108010074860 Factor Xa Proteins 0.000 description 1
• 241000282326 Felis catus Species 0.000 description 1
• 208000000571 Fibrocystic breast disease Diseases 0.000 description 1
• 206010016654 Fibrosis Diseases 0.000 description 1
• 241000700662 Fowlpox virus Species 0.000 description 1
• VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Natural products OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
• 102000013382 Gelatinases Human genes 0.000 description 1
• 108010026132 Gelatinases Proteins 0.000 description 1
• CHDWDBPJOZVZSE-KKUMJFAQSA-N Glu-Phe-Met Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCSC)C(O)=O CHDWDBPJOZVZSE-KKUMJFAQSA-N 0.000 description 1
• WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
• 102000006771 Gonadotropins Human genes 0.000 description 1
• 108010086677 Gonadotropins Proteins 0.000 description 1
• 241000219146 Gossypium Species 0.000 description 1
• 101710154606 Hemagglutinin Proteins 0.000 description 1
• 241001272567 Hominoidea Species 0.000 description 1
• 101000897493 Homo sapiens C-C motif chemokine 26 Proteins 0.000 description 1
• 101000862396 Homo sapiens Follicle-stimulating hormone receptor Proteins 0.000 description 1
• 101100456320 Homo sapiens NR3C2 gene Proteins 0.000 description 1
• 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 1
• 101000819111 Homo sapiens Trans-acting T-cell-specific transcription factor GATA-3 Proteins 0.000 description 1
• 101000818522 Homo sapiens fMet-Leu-Phe receptor Proteins 0.000 description 1
• 108090000144 Human Proteins Proteins 0.000 description 1
• 102000003839 Human Proteins Human genes 0.000 description 1
• CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
• 206010062767 Hypophysitis Diseases 0.000 description 1
• 101710093458 ICOS ligand Proteins 0.000 description 1
• 102100034980 ICOS ligand Human genes 0.000 description 1
• 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
• 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
• 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
• 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
• 229930010555 Inosine Natural products 0.000 description 1
• UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
• 101710203526 Integrase Proteins 0.000 description 1
• 108010008212 Integrin alpha4beta1 Proteins 0.000 description 1
• 108010005716 Interferon beta-1a Proteins 0.000 description 1
• 102000006992 Interferon-alpha Human genes 0.000 description 1
• 108010047761 Interferon-alpha Proteins 0.000 description 1
• 108010002335 Interleukin-9 Proteins 0.000 description 1
• 241000235649 Kluyveromyces Species 0.000 description 1
• 241000235058 Komagataella pastoris Species 0.000 description 1
• WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
• WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
• ZGUNAGUHMKGQNY-ZETCQYMHSA-N L-alpha-phenylglycine zwitterion Chemical compound OC(=O)[C@@H](N)C1=CC=CC=C1 ZGUNAGUHMKGQNY-ZETCQYMHSA-N 0.000 description 1
• ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
• HXEACLLIILLPRG-YFKPBYRVSA-N L-pipecolic acid Chemical compound [O-]C(=O)[C@@H]1CCCC[NH2+]1 HXEACLLIILLPRG-YFKPBYRVSA-N 0.000 description 1
• 102000023108 LH Receptors Human genes 0.000 description 1
• 108010011942 LH Receptors Proteins 0.000 description 1
• 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
• 239000005089 Luciferase Substances 0.000 description 1
• 206010025323 Lymphomas Diseases 0.000 description 1
• 101000686985 Mouse mammary tumor virus (strain C3H) Protein PR73 Proteins 0.000 description 1
• 102000016943 Muramidase Human genes 0.000 description 1
• 108010014251 Muramidase Proteins 0.000 description 1
• 241001529936 Murinae Species 0.000 description 1
• 101000605054 Mus musculus Epididymal-specific lipocalin-8 Proteins 0.000 description 1
• 241000699670 Mus sp. Species 0.000 description 1
• 241000186359 Mycobacterium Species 0.000 description 1
• 241000187644 Mycobacterium vaccae Species 0.000 description 1
• 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
• 230000004988 N-glycosylation Effects 0.000 description 1
• 108091061960 Naked DNA Proteins 0.000 description 1
• 229930193140 Neomycin Natural products 0.000 description 1
• 108091092724 Noncoding DNA Proteins 0.000 description 1
• 238000000636 Northern blotting Methods 0.000 description 1
• 101710163270 Nuclease Proteins 0.000 description 1
• 108091005461 Nucleic proteins Proteins 0.000 description 1
• 108700020497 Nucleopolyhedrovirus polyhedrin Proteins 0.000 description 1
• 239000004677 Nylon Substances 0.000 description 1
• 241000320412 Ogataea angusta Species 0.000 description 1
• 108010038807 Oligopeptides Proteins 0.000 description 1
• 102000015636 Oligopeptides Human genes 0.000 description 1
• 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
• 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
• 208000037273 Pathologic Processes Diseases 0.000 description 1
• 108091005804 Peptidases Proteins 0.000 description 1
• 108010067902 Peptide Library Proteins 0.000 description 1
• 235000004347 Perilla Nutrition 0.000 description 1
• 244000124853 Perilla frutescens Species 0.000 description 1
• 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
• 244000046052 Phaseolus vulgaris Species 0.000 description 1
• 108700001094 Plant Genes Proteins 0.000 description 1
• 229920000954 Polyglycolide Polymers 0.000 description 1
• 241001518143 Polypodium <fern> Species 0.000 description 1
• 108010035746 Pregnancy Proteins Proteins 0.000 description 1
• 102000008217 Pregnancy Proteins Human genes 0.000 description 1
• XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical class CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
• 108030003866 Prostaglandin-D synthases Proteins 0.000 description 1
• 102100033279 Prostaglandin-H2 D-isomerase Human genes 0.000 description 1
• 208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
• 239000004365 Protease Substances 0.000 description 1
• 101710176177 Protein A56 Proteins 0.000 description 1
• ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
• 108020004518 RNA Probes Proteins 0.000 description 1
• 239000003391 RNA probe Substances 0.000 description 1
• 108700005075 Regulator Genes Proteins 0.000 description 1
• 208000001647 Renal Insufficiency Diseases 0.000 description 1
• 241001068295 Replication defective viruses Species 0.000 description 1
• 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
• HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
• AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
• 101710141795 Ribonuclease inhibitor Proteins 0.000 description 1
• 229940122208 Ribonuclease inhibitor Drugs 0.000 description 1
• 102100037968 Ribonuclease inhibitor Human genes 0.000 description 1
• 108010003581 Ribulose-bisphosphate carboxylase Proteins 0.000 description 1
• CDMGBJANTYXAIV-UHFFFAOYSA-N SB 203580 Chemical compound C1=CC(S(=O)C)=CC=C1C1=NC(C=2C=CC(F)=CC=2)=C(C=2C=CN=CC=2)N1 CDMGBJANTYXAIV-UHFFFAOYSA-N 0.000 description 1
• ZQUSFAUAYSEREK-WKILWMFISA-N SB-239063 Chemical compound COC1=NC=CC(C=2N(C=NC=2C=2C=CC(F)=CC=2)[C@@H]2CC[C@@H](O)CC2)=N1 ZQUSFAUAYSEREK-WKILWMFISA-N 0.000 description 1
• 238000010818 SYBR green PCR Master Mix Methods 0.000 description 1
• 241000235070 Saccharomyces Species 0.000 description 1
• 240000000111 Saccharum officinarum Species 0.000 description 1
• 235000007201 Saccharum officinarum Nutrition 0.000 description 1
• 241000235347 Schizosaccharomyces pombe Species 0.000 description 1
• 108091081021 Sense strand Proteins 0.000 description 1
• 241000700584 Simplexvirus Species 0.000 description 1
• 208000000453 Skin Neoplasms Diseases 0.000 description 1
• 241000256248 Spodoptera Species 0.000 description 1
• 241000295644 Staphylococcaceae Species 0.000 description 1
• 241000187747 Streptomyces Species 0.000 description 1
• 235000021536 Sugar beet Nutrition 0.000 description 1
• 241000701093 Suid alphaherpesvirus 1 Species 0.000 description 1
• 241000282887 Suidae Species 0.000 description 1
• 241000282898 Sus scrofa Species 0.000 description 1
• 230000033540 T cell apoptotic process Effects 0.000 description 1
• 230000006052 T cell proliferation Effects 0.000 description 1
• 206010042971 T-cell lymphoma Diseases 0.000 description 1
• 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
• 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 1
• QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
• NAVMQTYZDKMPEU-UHFFFAOYSA-N Targretin Chemical compound CC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C(=C)C1=CC=C(C(O)=O)C=C1 NAVMQTYZDKMPEU-UHFFFAOYSA-N 0.000 description 1
• 206010043376 Tetanus Diseases 0.000 description 1
• RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
• 108091036066 Three prime untranslated region Proteins 0.000 description 1
• 102000006601 Thymidine Kinase Human genes 0.000 description 1
• 108020004440 Thymidine kinase Proteins 0.000 description 1
• 102000009843 Thyroglobulin Human genes 0.000 description 1
• 102100021386 Trans-acting T-cell-specific transcription factor GATA-3 Human genes 0.000 description 1
• 108091023040 Transcription factor Proteins 0.000 description 1
• 102000040945 Transcription factor Human genes 0.000 description 1
• 108020004566 Transfer RNA Proteins 0.000 description 1
• 208000025865 Ulcer Diseases 0.000 description 1
• 108091023045 Untranslated Region Proteins 0.000 description 1
• 102000006943 Uracil-DNA Glycosidase Human genes 0.000 description 1
• 108010072685 Uracil-DNA Glycosidase Proteins 0.000 description 1
• 101150117115 V gene Proteins 0.000 description 1
• 241000700618 Vaccinia virus Species 0.000 description 1
• 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
• 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
• FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
• OGQICQVSFDPSEI-UHFFFAOYSA-N Zorac Chemical compound N1=CC(C(=O)OCC)=CC=C1C#CC1=CC=C(SCCC2(C)C)C2=C1 OGQICQVSFDPSEI-UHFFFAOYSA-N 0.000 description 1
• JBPUGFODGPKTDW-SFHVURJKSA-N [(3s)-oxolan-3-yl] n-[[3-[[3-methoxy-4-(1,3-oxazol-5-yl)phenyl]carbamoylamino]phenyl]methyl]carbamate Chemical compound C=1C=C(C=2OC=NC=2)C(OC)=CC=1NC(=O)NC(C=1)=CC=CC=1CNC(=O)O[C@H]1CCOC1 JBPUGFODGPKTDW-SFHVURJKSA-N 0.000 description 1
• 150000001242 acetic acid derivatives Chemical class 0.000 description 1
• 230000021736 acetylation Effects 0.000 description 1
• 238000006640 acetylation reaction Methods 0.000 description 1
• 230000002378 acidificating effect Effects 0.000 description 1
• 230000010933 acylation Effects 0.000 description 1
• 238000005917 acylation reaction Methods 0.000 description 1
• 229960002964 adalimumab Drugs 0.000 description 1
• 230000002730 additional effect Effects 0.000 description 1
• 229960000643 adenine Drugs 0.000 description 1
• 210000001789 adipocyte Anatomy 0.000 description 1
• 239000002671 adjuvant Substances 0.000 description 1
• 238000001261 affinity purification Methods 0.000 description 1
• 238000013019 agitation Methods 0.000 description 1
• OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
• 229930002945 all-trans-retinaldehyde Natural products 0.000 description 1
• SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
• 239000013566 allergen Substances 0.000 description 1
• 108010001122 alpha(2)-microglobulin Proteins 0.000 description 1
• 230000009435 amidation Effects 0.000 description 1
• 238000007112 amidation reaction Methods 0.000 description 1
• 230000006229 amino acid addition Effects 0.000 description 1
• 229940126575 aminoglycoside Drugs 0.000 description 1
• BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
• 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
• 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
• 235000011130 ammonium sulphate Nutrition 0.000 description 1
• 238000012197 amplification kit Methods 0.000 description 1
• 230000019552 anatomical structure morphogenesis Effects 0.000 description 1
• 239000003098 androgen Substances 0.000 description 1
• 230000003322 aneuploid effect Effects 0.000 description 1
• 208000036878 aneuploidy Diseases 0.000 description 1
• 238000005571 anion exchange chromatography Methods 0.000 description 1
• 150000001450 anions Chemical class 0.000 description 1
• NUZWLKWWNNJHPT-UHFFFAOYSA-N anthralin Chemical compound C1C2=CC=CC(O)=C2C(=O)C2=C1C=CC=C2O NUZWLKWWNNJHPT-UHFFFAOYSA-N 0.000 description 1
• 239000003242 anti bacterial agent Substances 0.000 description 1
• 230000000844 anti-bacterial effect Effects 0.000 description 1
• 230000000340 anti-metabolite Effects 0.000 description 1
• 230000002682 anti-psoriatic effect Effects 0.000 description 1
• 229940100197 antimetabolite Drugs 0.000 description 1
• 239000002256 antimetabolite Substances 0.000 description 1
• 239000002246 antineoplastic agent Substances 0.000 description 1
• 229940041181 antineoplastic drug Drugs 0.000 description 1
• 239000003963 antioxidant agent Substances 0.000 description 1
• 235000006708 antioxidants Nutrition 0.000 description 1
• 239000003816 antisense DNA Substances 0.000 description 1
• 230000006907 apoptotic process Effects 0.000 description 1
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
• 229960003121 arginine Drugs 0.000 description 1
• 230000010516 arginylation Effects 0.000 description 1
• 238000003491 array Methods 0.000 description 1
• 210000001106 artificial yeast chromosome Anatomy 0.000 description 1
• 210000003567 ascitic fluid Anatomy 0.000 description 1
• 235000009582 asparagine Nutrition 0.000 description 1
• 229960001230 asparagine Drugs 0.000 description 1
• 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
• 230000001363 autoimmune Effects 0.000 description 1
• 238000011888 autopsy Methods 0.000 description 1
• 229960000190 bacillus calmette–guérin vaccine Drugs 0.000 description 1
• 239000000688 bacterial toxin Substances 0.000 description 1
• 108010058966 bacteriophage T7 induced DNA polymerase Proteins 0.000 description 1
• 229960004669 basiliximab Drugs 0.000 description 1
• 210000003651 basophil Anatomy 0.000 description 1
• 230000008901 benefit Effects 0.000 description 1
• 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
• 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
• 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
• DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
• 235000013734 beta-carotene Nutrition 0.000 description 1
• TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
• 239000011648 beta-carotene Substances 0.000 description 1
• 229960002747 betacarotene Drugs 0.000 description 1
• 229960002938 bexarotene Drugs 0.000 description 1
• 238000004166 bioassay Methods 0.000 description 1
• 230000003115 biocidal effect Effects 0.000 description 1
• 230000031018 biological processes and functions Effects 0.000 description 1
• 230000008512 biological response Effects 0.000 description 1
• 210000002459 blastocyst Anatomy 0.000 description 1
• 230000036765 blood level Effects 0.000 description 1
• 210000000988 bone and bone Anatomy 0.000 description 1
• 229940098773 bovine serum albumin Drugs 0.000 description 1
• 239000006172 buffering agent Substances 0.000 description 1
• 229910052791 calcium Inorganic materials 0.000 description 1
• 239000001506 calcium phosphate Substances 0.000 description 1
• 229910000389 calcium phosphate Inorganic materials 0.000 description 1
• 235000011010 calcium phosphates Nutrition 0.000 description 1
• 230000003185 calcium uptake Effects 0.000 description 1
• 239000002775 capsule Substances 0.000 description 1
• 150000001720 carbohydrates Chemical class 0.000 description 1
• 235000014633 carbohydrates Nutrition 0.000 description 1
• 230000021523 carboxylation Effects 0.000 description 1
• 238000006473 carboxylation reaction Methods 0.000 description 1
• 239000003054 catalyst Substances 0.000 description 1
• 238000005277 cation exchange chromatography Methods 0.000 description 1
• 239000006143 cell culture medium Substances 0.000 description 1
• 230000024245 cell differentiation Effects 0.000 description 1
• 230000012292 cell migration Effects 0.000 description 1
• 230000001413 cellular effect Effects 0.000 description 1
• 230000007969 cellular immunity Effects 0.000 description 1
• 230000007248 cellular mechanism Effects 0.000 description 1
• 230000036755 cellular response Effects 0.000 description 1
• 238000012412 chemical coupling Methods 0.000 description 1
• 125000003636 chemical group Chemical group 0.000 description 1
• 238000007385 chemical modification Methods 0.000 description 1
• 239000005081 chemiluminescent agent Substances 0.000 description 1
• 239000005482 chemotactic factor Substances 0.000 description 1
• 238000002512 chemotherapy Methods 0.000 description 1
• 108700010039 chimeric receptor Proteins 0.000 description 1
• 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
• VJYIFXVZLXQVHO-UHFFFAOYSA-N chlorsulfuron Chemical compound COC1=NC(C)=NC(NC(=O)NS(=O)(=O)C=2C(=CC=CC=2)Cl)=N1 VJYIFXVZLXQVHO-UHFFFAOYSA-N 0.000 description 1
• 235000012000 cholesterol Nutrition 0.000 description 1
• 210000002987 choroid plexus Anatomy 0.000 description 1
• 230000001684 chronic effect Effects 0.000 description 1
• 229960001265 ciclosporin Drugs 0.000 description 1
• 210000000078 claw Anatomy 0.000 description 1
• 230000003081 coactivator Effects 0.000 description 1
• 229940047120 colony stimulating factors Drugs 0.000 description 1
• 230000000052 comparative effect Effects 0.000 description 1
• 238000012875 competitive assay Methods 0.000 description 1
• 230000002860 competitive effect Effects 0.000 description 1
• 239000003636 conditioned culture medium Substances 0.000 description 1
• 238000012790 confirmation Methods 0.000 description 1
• 238000010276 construction Methods 0.000 description 1
• 239000000356 contaminant Substances 0.000 description 1
• 238000011109 contamination Methods 0.000 description 1
• 238000007796 conventional method Methods 0.000 description 1
• 238000011443 conventional therapy Methods 0.000 description 1
• 238000001816 cooling Methods 0.000 description 1
• 229920001577 copolymer Polymers 0.000 description 1
• 238000012937 correction Methods 0.000 description 1
• 230000000139 costimulatory effect Effects 0.000 description 1
• 230000008878 coupling Effects 0.000 description 1
• 238000010168 coupling process Methods 0.000 description 1
• 238000005859 coupling reaction Methods 0.000 description 1
• 108010015034 crustacyanins Proteins 0.000 description 1
• 229940109262 curcumin Drugs 0.000 description 1
• 235000012754 curcumin Nutrition 0.000 description 1
• 239000004148 curcumin Substances 0.000 description 1
• 229940121384 cxc chemokine receptor type 4 (cxcr4) antagonist Drugs 0.000 description 1
• 229930182912 cyclosporin Natural products 0.000 description 1
• UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 1
• 230000003436 cytoskeletal effect Effects 0.000 description 1
• 210000004292 cytoskeleton Anatomy 0.000 description 1
• 230000001086 cytosolic effect Effects 0.000 description 1
• 229960002806 daclizumab Drugs 0.000 description 1
• 238000007405 data analysis Methods 0.000 description 1
• 230000034994 death Effects 0.000 description 1
• 230000017858 demethylation Effects 0.000 description 1
• 238000010520 demethylation reaction Methods 0.000 description 1
• 230000001419 dependent effect Effects 0.000 description 1
• 230000008021 deposition Effects 0.000 description 1
• 230000001627 detrimental effect Effects 0.000 description 1
• 229960003957 dexamethasone Drugs 0.000 description 1
• UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
• 229960002086 dextran Drugs 0.000 description 1
• 239000000032 diagnostic agent Substances 0.000 description 1
• 229940039227 diagnostic agent Drugs 0.000 description 1
• 238000000502 dialysis Methods 0.000 description 1
• 235000005911 diet Nutrition 0.000 description 1
• 230000037213 diet Effects 0.000 description 1
• 235000014113 dietary fatty acids Nutrition 0.000 description 1
• VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 1
• 238000009792 diffusion process Methods 0.000 description 1
• 102000038379 digestive enzymes Human genes 0.000 description 1
• 108091007734 digestive enzymes Proteins 0.000 description 1
• 239000000539 dimer Substances 0.000 description 1
• XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
• 229960002986 dinoprostone Drugs 0.000 description 1
• 206010013023 diphtheria Diseases 0.000 description 1
• 208000035475 disorder Diseases 0.000 description 1
• 239000006185 dispersion Substances 0.000 description 1
• 238000006073 displacement reaction Methods 0.000 description 1
• 125000002228 disulfide group Chemical group 0.000 description 1
• 229960002311 dithranol Drugs 0.000 description 1
• PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
• 239000008298 dragée Substances 0.000 description 1
• 229940000406 drug candidate Drugs 0.000 description 1
• 238000009510 drug design Methods 0.000 description 1
• 238000009509 drug development Methods 0.000 description 1
• 238000012912 drug discovery process Methods 0.000 description 1
• 238000007878 drug screening assay Methods 0.000 description 1
• 238000002651 drug therapy Methods 0.000 description 1
• 230000004064 dysfunction Effects 0.000 description 1
• 235000013399 edible fruits Nutrition 0.000 description 1
• 229960000284 efalizumab Drugs 0.000 description 1
• 238000004520 electroporation Methods 0.000 description 1
• 230000008030 elimination Effects 0.000 description 1
• 238000003379 elimination reaction Methods 0.000 description 1
• 239000003995 emulsifying agent Substances 0.000 description 1
• 238000005538 encapsulation Methods 0.000 description 1
• 239000006274 endogenous ligand Substances 0.000 description 1
• 230000002357 endometrial effect Effects 0.000 description 1
• 230000002708 enhancing effect Effects 0.000 description 1
• 230000007515 enzymatic degradation Effects 0.000 description 1
• 230000009088 enzymatic function Effects 0.000 description 1
• 210000002615 epidermis Anatomy 0.000 description 1
• 210000000918 epididymis Anatomy 0.000 description 1
• 201000010063 epididymitis Diseases 0.000 description 1
• 210000002919 epithelial cell Anatomy 0.000 description 1
• 230000009786 epithelial differentiation Effects 0.000 description 1
• 150000002148 esters Chemical class 0.000 description 1
• 229960000403 etanercept Drugs 0.000 description 1
• 238000012869 ethanol precipitation Methods 0.000 description 1
• 102000013165 exonuclease Human genes 0.000 description 1
• 238000010195 expression analysis Methods 0.000 description 1
• 239000013613 expression plasmid Substances 0.000 description 1
• 102100021145 fMet-Leu-Phe receptor Human genes 0.000 description 1
• 229930195729 fatty acid Natural products 0.000 description 1
• 239000000194 fatty acid Substances 0.000 description 1
• 150000004665 fatty acids Chemical class 0.000 description 1
• 230000004720 fertilization Effects 0.000 description 1
• 230000001605 fetal effect Effects 0.000 description 1
• 210000003754 fetus Anatomy 0.000 description 1
• 210000002950 fibroblast Anatomy 0.000 description 1
• 230000004761 fibrosis Effects 0.000 description 1
• 150000002211 flavins Chemical class 0.000 description 1
• 238000000684 flow cytometry Methods 0.000 description 1
• 238000002866 fluorescence resonance energy transfer Methods 0.000 description 1
• 230000022244 formylation Effects 0.000 description 1
• 238000006170 formylation reaction Methods 0.000 description 1
• 238000013467 fragmentation Methods 0.000 description 1
• 238000006062 fragmentation reaction Methods 0.000 description 1
• 239000003205 fragrance Substances 0.000 description 1
• 239000001530 fumaric acid Substances 0.000 description 1
• 230000005714 functional activity Effects 0.000 description 1
• 238000002825 functional assay Methods 0.000 description 1
• 125000000524 functional group Chemical group 0.000 description 1
• 230000002538 fungal effect Effects 0.000 description 1
• 230000006251 gamma-carboxylation Effects 0.000 description 1
• 230000002496 gastric effect Effects 0.000 description 1
• 238000001502 gel electrophoresis Methods 0.000 description 1
• 108091008053 gene clusters Proteins 0.000 description 1
• 238000001476 gene delivery Methods 0.000 description 1
• 238000009650 gentamicin protection assay Methods 0.000 description 1
• 210000004602 germ cell Anatomy 0.000 description 1
• 239000011521 glass Substances 0.000 description 1
• 108060003196 globin Proteins 0.000 description 1
• 102000018146 globin Human genes 0.000 description 1
• 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
• 150000004676 glycans Chemical class 0.000 description 1
• 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
• 239000002622 gonadotropin Substances 0.000 description 1
• 239000008187 granular material Substances 0.000 description 1
• 239000003102 growth factor Substances 0.000 description 1
• 239000001963 growth medium Substances 0.000 description 1
• 150000003278 haem Chemical group 0.000 description 1
• 230000036541 health Effects 0.000 description 1
• 238000010438 heat treatment Methods 0.000 description 1
• 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
• 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
• 230000002363 herbicidal effect Effects 0.000 description 1
• 239000004009 herbicide Substances 0.000 description 1
• 125000005842 heteroatom Chemical group 0.000 description 1
• 238000004128 high performance liquid chromatography Methods 0.000 description 1
• 238000013537 high throughput screening Methods 0.000 description 1
• 150000002411 histidines Chemical class 0.000 description 1
• 230000013632 homeostatic process Effects 0.000 description 1
• 229940088597 hormone Drugs 0.000 description 1
• 239000005556 hormone Substances 0.000 description 1
• 102000046113 human FSHR Human genes 0.000 description 1
• 210000003917 human chromosome Anatomy 0.000 description 1
• 150000003840 hydrochlorides Chemical class 0.000 description 1
• 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
• 230000033444 hydroxylation Effects 0.000 description 1
• 238000005805 hydroxylation reaction Methods 0.000 description 1
• 229960002591 hydroxyproline Drugs 0.000 description 1
• 210000002865 immune cell Anatomy 0.000 description 1
• 208000026278 immune system disease Diseases 0.000 description 1
• 230000003053 immunization Effects 0.000 description 1
• 238000002649 immunization Methods 0.000 description 1
• 230000000984 immunochemical effect Effects 0.000 description 1
• 229960001438 immunostimulant agent Drugs 0.000 description 1
• 239000003022 immunostimulating agent Substances 0.000 description 1
• 230000003308 immunostimulating effect Effects 0.000 description 1
• 230000006872 improvement Effects 0.000 description 1
• 238000010249 in-situ analysis Methods 0.000 description 1
• 230000002779 inactivation Effects 0.000 description 1
• QNRXNRGSOJZINA-UHFFFAOYSA-N indoline-2-carboxylic acid Chemical compound C1=CC=C2NC(C(=O)O)CC2=C1 QNRXNRGSOJZINA-UHFFFAOYSA-N 0.000 description 1
• 230000002458 infectious effect Effects 0.000 description 1
• 208000000509 infertility Diseases 0.000 description 1
• 230000008595 infiltration Effects 0.000 description 1
• 238000001764 infiltration Methods 0.000 description 1
• 229960000598 infliximab Drugs 0.000 description 1
• 206010022000 influenza Diseases 0.000 description 1
• 239000002054 inoculum Substances 0.000 description 1
• 229910052500 inorganic mineral Inorganic materials 0.000 description 1
• 229960003786 inosine Drugs 0.000 description 1
• 230000010354 integration Effects 0.000 description 1
• 229940074383 interleukin-11 Drugs 0.000 description 1
• 108040006852 interleukin-4 receptor activity proteins Proteins 0.000 description 1
• 238000001361 intraarterial administration Methods 0.000 description 1
• 238000000185 intracerebroventricular administration Methods 0.000 description 1
• 238000007912 intraperitoneal administration Methods 0.000 description 1
• 238000007852 inverse PCR Methods 0.000 description 1
• 238000011835 investigation Methods 0.000 description 1
• 230000026045 iodination Effects 0.000 description 1
• 238000006192 iodination reaction Methods 0.000 description 1
• 239000002085 irritant Substances 0.000 description 1
• 231100000021 irritant Toxicity 0.000 description 1
• 210000002510 keratinocyte Anatomy 0.000 description 1
• 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 1
• 201000006370 kidney failure Diseases 0.000 description 1
• 238000002372 labelling Methods 0.000 description 1
• 101150066555 lacZ gene Proteins 0.000 description 1
• 230000002045 lasting effect Effects 0.000 description 1
• 239000000787 lecithin Substances 0.000 description 1
• 229940067606 lecithin Drugs 0.000 description 1
• 235000010445 lecithin Nutrition 0.000 description 1
• 229960000681 leflunomide Drugs 0.000 description 1
• VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 description 1
• 238000000670 ligand binding assay Methods 0.000 description 1
• 108020001756 ligand binding domains Proteins 0.000 description 1
• 230000004576 lipid-binding Effects 0.000 description 1
• 239000007791 liquid phase Substances 0.000 description 1
• 238000011068 loading method Methods 0.000 description 1
• 230000004807 localization Effects 0.000 description 1
• 150000004668 long chain fatty acids Chemical class 0.000 description 1
• 238000004020 luminiscence type Methods 0.000 description 1
• IQPNAANSBPBGFQ-UHFFFAOYSA-N luteolin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C(O)=C1 IQPNAANSBPBGFQ-UHFFFAOYSA-N 0.000 description 1
• LRDGATPGVJTWLJ-UHFFFAOYSA-N luteolin Natural products OC1=CC(O)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 LRDGATPGVJTWLJ-UHFFFAOYSA-N 0.000 description 1
• 235000009498 luteolin Nutrition 0.000 description 1
• 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
• 229960000274 lysozyme Drugs 0.000 description 1
• 239000004325 lysozyme Substances 0.000 description 1
• 235000010335 lysozyme Nutrition 0.000 description 1
• 229920002521 macromolecule Polymers 0.000 description 1
• 239000006249 magnetic particle Substances 0.000 description 1
• 230000014759 maintenance of location Effects 0.000 description 1
• 150000002690 malonic acid derivatives Chemical class 0.000 description 1
• 238000013507 mapping Methods 0.000 description 1
• 230000008774 maternal effect Effects 0.000 description 1
• 201000001441 melanoma Diseases 0.000 description 1
• 238000002844 melting Methods 0.000 description 1
• 230000008018 melting Effects 0.000 description 1
• 230000002503 metabolic effect Effects 0.000 description 1
• 230000037353 metabolic pathway Effects 0.000 description 1
• 229910021645 metal ion Inorganic materials 0.000 description 1
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
• 230000011987 methylation Effects 0.000 description 1
• 238000007069 methylation reaction Methods 0.000 description 1
• 244000000010 microbial pathogen Species 0.000 description 1
• 238000000520 microinjection Methods 0.000 description 1
• 238000010232 migration assay Methods 0.000 description 1
• 230000003278 mimic effect Effects 0.000 description 1
• 239000011707 mineral Substances 0.000 description 1
• ZAHQPTJLOCWVPG-UHFFFAOYSA-N mitoxantrone dihydrochloride Chemical compound Cl.Cl.O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO ZAHQPTJLOCWVPG-UHFFFAOYSA-N 0.000 description 1
• 238000002156 mixing Methods 0.000 description 1
• 230000037230 mobility Effects 0.000 description 1
• 230000009149 molecular binding Effects 0.000 description 1
• 239000000178 monomer Substances 0.000 description 1
• 210000003097 mucus Anatomy 0.000 description 1
• 210000003205 muscle Anatomy 0.000 description 1
• RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 description 1
• 229960004866 mycophenolate mofetil Drugs 0.000 description 1
• 230000007498 myristoylation Effects 0.000 description 1
• QVRVXSZKCXFBTE-UHFFFAOYSA-N n-[4-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)butyl]-2-(2-fluoroethoxy)-5-methylbenzamide Chemical compound C1C=2C=C(OC)C(OC)=CC=2CCN1CCCCNC(=O)C1=CC(C)=CC=C1OCCF QVRVXSZKCXFBTE-UHFFFAOYSA-N 0.000 description 1
• OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 1
• 229930014626 natural product Natural products 0.000 description 1
• 239000013642 negative control Substances 0.000 description 1
• 230000010807 negative regulation of binding Effects 0.000 description 1
• 230000031990 negative regulation of inflammatory response Effects 0.000 description 1
• 229960004927 neomycin Drugs 0.000 description 1
• 210000005170 neoplastic cell Anatomy 0.000 description 1
• 201000008383 nephritis Diseases 0.000 description 1
• 210000000653 nervous system Anatomy 0.000 description 1
• 229960003753 nitric oxide Drugs 0.000 description 1
• 230000009871 nonspecific binding Effects 0.000 description 1
• 238000010606 normalization Methods 0.000 description 1
• 230000031787 nutrient reservoir activity Effects 0.000 description 1
• 229920001778 nylon Polymers 0.000 description 1
• 238000011275 oncology therapy Methods 0.000 description 1
• 229950010444 onercept Drugs 0.000 description 1
• 210000000056 organ Anatomy 0.000 description 1
• 230000003647 oxidation Effects 0.000 description 1
• 238000007254 oxidation reaction Methods 0.000 description 1
• 239000006179 pH buffering agent Substances 0.000 description 1
• 210000000496 pancreas Anatomy 0.000 description 1
• 238000007911 parenteral administration Methods 0.000 description 1
• 230000036961 partial effect Effects 0.000 description 1
• 244000052769 pathogen Species 0.000 description 1
• 230000009054 pathological process Effects 0.000 description 1
• 239000013610 patient sample Substances 0.000 description 1
• 230000006320 pegylation Effects 0.000 description 1
• 239000008188 pellet Substances 0.000 description 1
• XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
• 210000001322 periplasm Anatomy 0.000 description 1
• 210000003245 peritoneal mesothelial cell Anatomy 0.000 description 1
• 238000002823 phage display Methods 0.000 description 1
• 239000012071 phase Substances 0.000 description 1
• 239000003016 pheromone Substances 0.000 description 1
• 239000010452 phosphate Substances 0.000 description 1
• 150000003905 phosphatidylinositols Chemical class 0.000 description 1
• 108010082527 phosphinothricin N-acetyltransferase Proteins 0.000 description 1
• 229940080469 phosphocellulose Drugs 0.000 description 1
• 150000004713 phosphodiesters Chemical class 0.000 description 1
• 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
• 230000026731 phosphorylation Effects 0.000 description 1
• 238000006366 phosphorylation reaction Methods 0.000 description 1
• 230000035479 physiological effects, processes and functions Effects 0.000 description 1
• 230000035790 physiological processes and functions Effects 0.000 description 1
• 229940068065 phytosterols Drugs 0.000 description 1
• 239000006187 pill Substances 0.000 description 1
• KASDHRXLYQOAKZ-ZPSXYTITSA-N pimecrolimus Chemical compound C/C([C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@@H](OC)C[C@@H](C)C/C(C)=C/[C@H](C(C[C@H](O)[C@H]1C)=O)CC)=C\[C@@H]1CC[C@@H](Cl)[C@H](OC)C1 KASDHRXLYQOAKZ-ZPSXYTITSA-N 0.000 description 1
• 229960005330 pimecrolimus Drugs 0.000 description 1
• 210000003635 pituitary gland Anatomy 0.000 description 1
• 210000002826 placenta Anatomy 0.000 description 1
• 235000002378 plant sterols Nutrition 0.000 description 1
• 210000002381 plasma Anatomy 0.000 description 1
• 239000013600 plasmid vector Substances 0.000 description 1
• 229920000747 poly(lactic acid) Polymers 0.000 description 1
• 229920000573 polyethylene Polymers 0.000 description 1
• 239000004633 polyglycolic acid Substances 0.000 description 1
• 239000004626 polylactic acid Substances 0.000 description 1
• 229920000642 polymer Polymers 0.000 description 1
• 229920001282 polysaccharide Polymers 0.000 description 1
• 239000005017 polysaccharide Substances 0.000 description 1
• 239000013641 positive control Substances 0.000 description 1
• 230000004481 post-translational protein modification Effects 0.000 description 1
• 230000032361 posttranscriptional gene silencing Effects 0.000 description 1
• 230000003389 potentiating effect Effects 0.000 description 1
• 201000011461 pre-eclampsia Diseases 0.000 description 1
• 239000002243 precursor Substances 0.000 description 1
• 230000002028 premature Effects 0.000 description 1
• 230000013823 prenylation Effects 0.000 description 1
• 230000037452 priming Effects 0.000 description 1
• 230000009696 proliferative response Effects 0.000 description 1
• 230000001915 proofreading effect Effects 0.000 description 1
• 230000000644 propagated effect Effects 0.000 description 1
• XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
• YIBNHAJFJUQSRA-YNNPMVKQSA-N prostaglandin H2 Chemical compound C1[C@@H]2OO[C@H]1[C@H](/C=C/[C@@H](O)CCCCC)[C@H]2C\C=C/CCCC(O)=O YIBNHAJFJUQSRA-YNNPMVKQSA-N 0.000 description 1
• 235000019419 proteases Nutrition 0.000 description 1
• 230000017854 proteolysis Effects 0.000 description 1
• 210000001938 protoplast Anatomy 0.000 description 1
• 229940043131 pyroglutamate Drugs 0.000 description 1
• 238000011002 quantification Methods 0.000 description 1
• 229960001285 quercetin Drugs 0.000 description 1
• 235000005875 quercetin Nutrition 0.000 description 1
• 230000006340 racemization Effects 0.000 description 1
• 230000002285 radioactive effect Effects 0.000 description 1
• ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
• 230000009103 reabsorption Effects 0.000 description 1
• 230000008707 rearrangement Effects 0.000 description 1
• 229940038850 rebif Drugs 0.000 description 1
• 239000000018 receptor agonist Substances 0.000 description 1
• 229940044601 receptor agonist Drugs 0.000 description 1
• 108010003189 recombinant human tumor necrosis factor-binding protein-1 Proteins 0.000 description 1
• 230000008929 regeneration Effects 0.000 description 1
• 238000011069 regeneration method Methods 0.000 description 1
• 230000008521 reorganization Effects 0.000 description 1
• 230000009933 reproductive health Effects 0.000 description 1
• 210000004994 reproductive system Anatomy 0.000 description 1
• 108091008146 restriction endonucleases Proteins 0.000 description 1
• 230000000717 retained effect Effects 0.000 description 1
• 230000002207 retinal effect Effects 0.000 description 1
• NCYCYZXNIZJOKI-OVSJKPMPSA-N retinal group Chemical group C\C(=C/C=O)\C=C\C=C(\C=C\C1=C(CCCC1(C)C)C)/C NCYCYZXNIZJOKI-OVSJKPMPSA-N 0.000 description 1
• 229930002330 retinoic acid Natural products 0.000 description 1
• 108091010987 retinoic acid binding proteins Proteins 0.000 description 1
• 102000003702 retinoic acid receptors Human genes 0.000 description 1
• 108090000064 retinoic acid receptors Proteins 0.000 description 1
• 229960000342 retinol acetate Drugs 0.000 description 1
• 235000019173 retinyl acetate Nutrition 0.000 description 1
• 239000011770 retinyl acetate Substances 0.000 description 1
• 206010039083 rhinitis Diseases 0.000 description 1
• 239000003161 ribonuclease inhibitor Substances 0.000 description 1
• 239000007320 rich medium Substances 0.000 description 1
• 238000007363 ring formation reaction Methods 0.000 description 1
• 210000003296 saliva Anatomy 0.000 description 1
• 239000012266 salt solution Substances 0.000 description 1
• 239000012898 sample dilution Substances 0.000 description 1
• 239000006152 selective media Substances 0.000 description 1
• 238000000926 separation method Methods 0.000 description 1
• 230000000405 serological effect Effects 0.000 description 1
• 230000001568 sexual effect Effects 0.000 description 1
• 230000019491 signal transduction Effects 0.000 description 1
• 230000011664 signaling Effects 0.000 description 1
• 229960002930 sirolimus Drugs 0.000 description 1
• QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
• 201000000849 skin cancer Diseases 0.000 description 1
• 231100000430 skin reaction Toxicity 0.000 description 1
• 239000002002 slurry Substances 0.000 description 1
• 210000002460 smooth muscle Anatomy 0.000 description 1
• 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
• 230000000392 somatic effect Effects 0.000 description 1
• 238000004611 spectroscopical analysis Methods 0.000 description 1
• 230000006641 stabilisation Effects 0.000 description 1
• 238000011105 stabilization Methods 0.000 description 1
• 230000010473 stable expression Effects 0.000 description 1
• 210000000130 stem cell Anatomy 0.000 description 1
• 230000010009 steroidogenesis Effects 0.000 description 1
• 230000004936 stimulating effect Effects 0.000 description 1
• 210000002536 stromal cell Anatomy 0.000 description 1
• 125000001424 substituent group Chemical group 0.000 description 1
• 230000019635 sulfation Effects 0.000 description 1
• 238000005670 sulfation reaction Methods 0.000 description 1
• 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
• 231100000617 superantigen Toxicity 0.000 description 1
• 230000001629 suppression Effects 0.000 description 1
• 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
• 230000004083 survival effect Effects 0.000 description 1
• 210000004243 sweat Anatomy 0.000 description 1
• 210000001179 synovial fluid Anatomy 0.000 description 1
• 238000001308 synthesis method Methods 0.000 description 1
• 239000006188 syrup Substances 0.000 description 1
• 235000020357 syrup Nutrition 0.000 description 1
• 238000007910 systemic administration Methods 0.000 description 1
• 239000003826 tablet Substances 0.000 description 1
• 229960001967 tacrolimus Drugs 0.000 description 1
• QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
• 229960000565 tazarotene Drugs 0.000 description 1
• 150000003505 terpenes Chemical class 0.000 description 1
• 238000011285 therapeutic regimen Methods 0.000 description 1
• ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 description 1
• 229940113082 thymine Drugs 0.000 description 1
• 229960002175 thyroglobulin Drugs 0.000 description 1
• 238000012090 tissue culture technique Methods 0.000 description 1
• 230000000699 topical effect Effects 0.000 description 1
• 231100000419 toxicity Toxicity 0.000 description 1
• 230000001988 toxicity Effects 0.000 description 1
• 239000003053 toxin Substances 0.000 description 1
• 231100000765 toxin Toxicity 0.000 description 1
• 108700012359 toxins Proteins 0.000 description 1
• 238000012549 training Methods 0.000 description 1
• FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
• VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
• 238000010361 transduction Methods 0.000 description 1
• 230000026683 transduction Effects 0.000 description 1
• 230000001131 transforming effect Effects 0.000 description 1
• 230000001052 transient effect Effects 0.000 description 1
• 238000002054 transplantation Methods 0.000 description 1
• 229960001727 tretinoin Drugs 0.000 description 1
• QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
• GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 description 1
• GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 description 1
• 229960001641 troglitazone Drugs 0.000 description 1
• LZMSXDHGHZKXJD-VJANTYMQSA-N trypanothione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H]1CSSC[C@H](NC(=O)CC[C@H](N)C(O)=O)C(=O)NCC(=O)NCCCNCCCCNC(=O)CNC1=O LZMSXDHGHZKXJD-VJANTYMQSA-N 0.000 description 1
• 210000005239 tubule Anatomy 0.000 description 1
• 230000005748 tumor development Effects 0.000 description 1
• 230000029069 type 2 immune response Effects 0.000 description 1
• 238000010798 ubiquitination Methods 0.000 description 1
• 230000034512 ubiquitination Effects 0.000 description 1
• 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
• 241001430294 unidentified retrovirus Species 0.000 description 1
• 238000011144 upstream manufacturing Methods 0.000 description 1
• DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
• 229940045145 uridine Drugs 0.000 description 1
• 238000002255 vaccination Methods 0.000 description 1
• 235000013311 vegetables Nutrition 0.000 description 1
• 210000003501 vero cell Anatomy 0.000 description 1
• 108090000195 villin Proteins 0.000 description 1
• 235000019155 vitamin A Nutrition 0.000 description 1
• 239000011719 vitamin A Substances 0.000 description 1
• NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
• 229940045997 vitamin a Drugs 0.000 description 1
• 230000003442 weekly effect Effects 0.000 description 1
• 239000000080 wetting agent Substances 0.000 description 1
• OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1